



## **Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference**

November 25, 2014

**Live Audio Webcasts will be on December 2nd and 3rd, 2014**

SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.

On December 2 at 11:40am Eastern Time (8:40am Pacific Time) he will make a presentation at the 2014 Deutsche Bank BioFEST in Boston.

On December 3 at 12:00pm Eastern Time (9:00am Pacific Time) he will make a presentation at the 26<sup>th</sup> Annual Piper Jaffray Healthcare Conference in New York City.

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

### **About Neurocrine Biosciences**

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at <http://www.neurocrine.com>.

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Investor Relations, (858) 617-7600